Research and Development
CohBar MBT Pipeline
CohBar’s lead clinical development program is based on MOTS-c, an MDP discovered in 2012 by our founders and their academic collaborators. Their research has shown that MOTS-c plays a significant role in the regulation of metabolism. We have developed optimized analogs of the MOTS-c peptide and identified two of these analogs, CB4209 and CB4211, as drug candidates for advancement into IND-enabling activities.
The drug candidates have demonstrated significant therapeutic potential in preclinical models for the treatment of obesity, with additional ongoing studies to determine their therapeutic potential for the treatment of nonalcoholic steatohepatitis (NASH), an advanced form of fatty liver disease, and as an add-on to other drugs for the treatment of Type-2 diabetes.
SHLP-6 and SHLP-2 are small humanin-like peptides. We are evaluating SHLP-6 for potential utility in the suppression of tumor angiogenesis and apoptosis induction in the treatment of cancer. SHLP-2, a part of our in-licensed MDP portfolio, has shown to have protective effects in vitro against neuronal toxicity and may be useful in the treatment of Alzheimer’s disease.
In addition to our two lead MOTS-c analogs, CB4209 and CB4211, and the other peptides in our portfolio, our scientists have also discovered more than 50 new biologically active MDPs encoded within the mitochondrial genome.
We continue to evaluate our new and existing MDPs to prioritize and optimize our clinical development efforts and resources and our targeting of age-related diseases.